xylometazoline

Small moleculeexperimental

Xylometazoline, also spelled xylomethazoline, is a medication which is used to improve symptoms of nasal congestion, allergic rhinitis, and sinusitis. Xylometazoline was patented in 1956 and came into medical use in 1959. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The drug works by stimulating adrenergic receptors on the lamina propria of blood vessels in the nose. The decongestant effect is due to constriction of large veins in the nose which swell up during the inflammation of any infection or allergy of the nose. The smaller arteries are also constricted and this causes the colour of the nasal epithelium to be visibly paler after dosage. The standard adult solution strength is 0.1% w/v xylometazoline (or 1 mg per 1 mL solution), and the dose for children under 12 is usually 0.05% (0.5 mg/mL). — NCATS

Clinical trial activity

14 trials · 21 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jan 1, 2004 (NCT00630474)

Timeline

2000s

Jan 1, 2007
Earliest Phase 3 Sponsor(trial)

2020s

Jan 1, 2024
Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1

Mol. weight: 244.38 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

Also known as

2-(4'-tert-butyl-2',6'-dimethylphenylmethyl)imidazoline
amidrin
balkis
balminil
balminil
chlorohist-la
decongest
espa-rhin
gelonasal
idasal
imidin
nasan
nasengel al
nasengel ratiopharm
nasenspray al
nasenspray ratiopharm
nasentropfen al
nasentropfen ratiopharm
nazo-mist
neo-synephrine ii
neo-synephrine ii
novorin
otradrops
otradrops
otradrops
otraspray
otraspray
otraspray
otriven
otrivin
otrivine
otrivine
otrivine
otrivine hay fever for
otrivin hcl
otrivin mentol
rapako
rhinoxilin
schnupfen endrine
snup
stas
xylometazoline
xylometazoline
xylometazoline
xylometazoline
xylometazoline
xylometazoline
xylometazoline
xylometazoline
xylometazoline
xylometazoline hcl
xylometazoline hcl
xylometazoline hcl
xylometazoline hydrochloride
xylometazoline hydrochloride
xylometazoline hydrochloride
xylometazoline hydrochloride
xylometazoline hydrochloride
xylometazoline monohydrochloride
xylomethazoline
xylomethazoline
xylomet hcl

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT06801522	Phase 2/Phase 3 (Phase 3)	Dec 1, 2024	Shaheed Zulfiqar Ali Bhutto Medical University
NCT06443255	Phase 3	Jul 1, 2024	University of Copenhagen
NCT05334017	Phase 4	Sep 8, 2022	University of Copenhagen
NCT05804123	N/A	Oct 28, 2021	Anabio, Thai Binh University of Medicine and Pharmacy
NCT03424889	N/A	Apr 1, 2018	All India Institute of Medical Sciences
NCT03439436	Phase 3	Feb 26, 2018	I.M. Sechenov First Moscow State Medical University, Johnson and Johnson, Pavlov First Saint Petersburg State Medical University, Research Clinical Centre of the Russian Railways, JSC
NCT03072173	N/A	Mar 1, 2017	Lovisenberg Diakonale Hospital, Lund University
NCT02557269	Phase 4	May 1, 2015	Association Asthma, Bulgaria, Medical University of Sofia, Nasaleze
NCT01966965	Phase 3	Jul 1, 2014	Phytopharm
NCT02146300	N/A	Mar 1, 2014	University of Oslo, University of Oulu
NCT01351298	Phase 4	Jun 1, 2011	University of British Columbia
NCT00452270	Phase 3	Mar 1, 2007	Novartis
NCT00622817	N/A	Oct 1, 2004	Tel Aviv University
NCT00630474	Phase 4	Jan 1, 2004	University of Zurich

Showing 14 of 14 trials

Page 1 / 1

Organizations

Research & Development (21)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
University of Copenhagen	Academic/Hospital	2	2	2	2022
All India Institute of Medical Sciences	Academic/Hospital	1	1	1	2018
Anabio	For profit	1	1	1	2021
Association Asthma, Bulgaria	Academic/Hospital	1	1	1	2015
I.M. Sechenov First Moscow State Medical University	Academic/Hospital	1	0	1	2018
Johnson and Johnson	For profit	1	1	1	2018
Lovisenberg Diakonale Hospital	Academic/Hospital	1	1	1	2017
Lund University	Academic/Hospital	1	0	1	2017
Medical University of Sofia	Academic/Hospital	1	0	1	2015
Nasaleze	For profit	1	0	1	2015
Novartis	For profit	1	1	1	2007
Pavlov First Saint Petersburg State Medical University	Academic/Hospital	1	0	1	2018
Phytopharm	For profit	1	1	1	2014
Research Clinical Centre of the Russian Railways, JSC	Academic/Hospital	1	0	1	2018
Shaheed Zulfiqar Ali Bhutto Medical University	Academic/Hospital	1	1	1	2024
Tel Aviv University	Academic/Hospital	1	1	1	2004
Thai Binh University of Medicine and Pharmacy	Academic/Hospital	1	0	1	2021
University of British Columbia	Academic/Hospital	1	1	1	2011
University of Oslo	Academic/Hospital	1	1	1	2014
University of Oulu	Academic/Hospital	1	0	1	2014

21 organizations

Page 1 / 2